Ledipasvir + GS-9451+peginterferon and ribavrin (PR) for six or 12 weeks achieves a high SVR12 in treatment naive genotype 1 IL28B CC patients

被引：0
|
作者：
Thompson, A. [1 ]
Shiffman, M. [2 ]
Pianko, S. [3 ]
Kanwar, B. [4 ]
Mchutchison, J. [4 ]
Muir, A. J. [5 ]
Lee, S. [6 ]
George, J. [7 ]
机构：
[1] St Vincents Hosp Melbourne, Melbourne, Vic, Australia
[2] Liver Inst Virginia, Norfolk, VA USA
[3] Monash Med Ctr, Clayton, Vic 3168, Australia
[4] Gilead Sci Inc, Foster City, CA 94404 USA
[5] Duke Clin Res Inst, Durham, NC USA
[6] Univ Calgary, Calgary, AB, Canada
[7] Westmead Hosp, Westmead, NSW 2145, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2013年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：173 / 173
页数：1
相关论文
共 26 条
  • [1] GS-5885+GS-9451+PEGINTERFERON AND RIBAVIRIN (PR) FOR SIX OR TWELVE WEEKS ACHIEVES HIGH SVR12 RATES IN TREATMENT-NAIVE GENOTYPE 1 IL28B CC PATIENTS
    Thompson, A.
    Han, S.
    Shiffman, M. L.
    Rossaro, L.
    Ghalib, R.
    Beavers, K.
    Pianko, S.
    Wu, X.
    Pang, P. S.
    Rossi, S.
    McHutchison, J.
    Muir, A.
    Lee, S.
    George, J.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S29 - S29
  • [2] Six Weeks of a NS5A Inhibitor (GS-5885), Protease Inhibitor (GS-9451) plus Peginterferon/Ribavirin (PR) Achieves High SVR4 Rates in Genotype 1 IL28B CC Treatment Naive HCV Patients: Interim Results of a Prospective, Randomized Trial
    Thompson, Alexander J.
    Shiffman, Mitchell L.
    Rossaro, Lorenzo
    Ghalib, Reem
    Han, Steven-Huy B.
    Beavers, Kimberly L.
    Pianko, Stephen
    George, Jacob
    He, Lin
    Wu, Xiaoru
    Flores, Nikki
    Pang, Phil S.
    Rossi, Stephen J.
    McHutchison, John G.
    Lee, Samuel S.
    Muir, Andrew J.
    HEPATOLOGY, 2012, 56 : 556A - 557A
  • [3] 100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL
    Bronowicki, J-P
    Hezode, C.
    Bengtsson, L.
    Pol, S.
    Bourliere, M.
    Serfaty, L.
    de Ledinghen, V.
    Tran, A.
    Benhamou, Y.
    Grange, J-D
    Mathurin, P.
    Marcellin, P.
    Trepo, C.
    Zarski, J-P
    Seepersaud, S.
    Kelliher, K.
    Botfield, M.
    Pawlotsky, J-M
    JOURNAL OF HEPATOLOGY, 2012, 56 : S430 - S431
  • [4] HIGH SVR12 WITH 16 WEEKS OF TEGOBUVIR AND GS-9256 WITH PEGINTERFERON-ALFA 2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS
    Nelson, D. R.
    Lawitz, E.
    Bain, V.
    Gitlin, N.
    Hawkins, T.
    Marotta, P.
    Workowski, K.
    Flamm, S.
    Pang, P. S.
    McHutchison, J. G.
    McNally, J.
    Urbanek, P.
    Yoshida, E. M.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S6 - S7
  • [5] SOFOSBUVIR plus PEGINTERFERON plus RIBAVIRIN FOR 12 WEEKS ACHIEVES 90% SVR12 IN GENOTYPE 1, 4, 5, OR 6 HCV INFECTED PATIENTS: THE NEUTRINO STUDY
    Lawitz, E.
    Wyles, D.
    Davis, M.
    Rodriguez-Torres, M.
    Reddy, K. R.
    Kowdley, K. V.
    Svarovskaia, E.
    Jiang, D.
    McNally, J.
    Brainard, D. M.
    Symonds, W. T.
    McHutchison, J. G.
    Nyberg, L.
    Younossi, Z.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S567 - S567
  • [6] SVR12 is higher than SVR24 in treatment-naive hepatitis C genotype 1 patients treated with peginterferon plus ribavirin
    Thorlund, Kristian
    Druyts, Eric
    Mills, Edward J.
    CLINICAL EPIDEMIOLOGY, 2014, 6 : 49 - 58
  • [7] EFFICACY AND SAFETY OF WEIGHT-BASED REGIMENS OF TARIBAVIRIN OR RIBAVIRIN, GIVEN WITH PEGINTERFERON ALFA-2B, AT 12 WEEKS AFTER TREATMENT (SVR12) IN NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC-HEPATITIS C
    Poordad, F.
    Lawitz, E.
    Pozza, R.
    Shiffman, M.
    Bacon, B.
    Godofsky, E.
    Halliman, D.
    Heise, J.
    Chun, E.
    Hammond, J.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S8 - S8
  • [8] VX-222/TELAPREVIR IN COMBINATION WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS TREATED FOR 12 WEEKS: ZENITH STUDY, SVR12 INTERIM ANALYSIS
    Nelson, David R.
    Gane, Edward J.
    Jacobson, Ira M.
    Di Bisceglie, Adrian M.
    Alves, Katia
    Koziel, Margaret J.
    De Souza, Cynthia
    Kieffer, Tara L.
    George, Shelley
    Rosario, Maria
    Kauffman, Robert S.
    Sulkowski, Mark S.
    HEPATOLOGY, 2011, 54 : 1435A - 1435A
  • [9] ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS)
    Buti, M.
    Flisiak, R.
    Rasenack, J.
    Davis, G.
    Alberti, A.
    Goeser, T.
    Stanciu, C.
    Chuang, W. -L.
    Tabak, F.
    Kao, J. -H.
    Streinu-Cercel, A.
    Hofstetter, G.
    Wang, J.
    Avila, C.
    Orsenigo, R.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S572 - S572
  • [10] RAPID VIROLOGICAL RESPONSE(RVR) VS IL28B CC GENOTYPE IN HCV-1 INFECTED PATIENTS TREATED WITH AN INDIVIDUALIZED COURSE OF PEGINTERFERON (PEGIFN) AND WEIGHT BASED RIBAVRIN (RBV)
    Mangia, Alessandra
    Thompson, Alexander J.
    Santoro, Rosanna
    Mottola, Leonardo
    Piazzolla, Valeria
    Petruzzellis, Daniela
    Minerva, Nicola
    Bacca, Donato
    Goldstein, David B.
    McHutchison, John G.
    HEPATOLOGY, 2010, 52 (04) : 750A - 751A
123